← Back to Clinical Trials
Recruiting NCT07104097

NCT07104097 Comparison Between 2 Techniques for Lumbar-ESPB

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07104097
Status Recruiting
Phase
Sponsor Papa Giovanni XXIII Hospital
Condition Hip Surgery
Study Type INTERVENTIONAL
Enrollment 44 participants
Start Date 2025-10-06
Primary Completion 2026-08-20

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
spinal anesthesiasuperficial erector spinal plane block (ESPB)deep (inter laminar) erector spinal plane block (ESPB)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 44 participants in total. It began in 2025-10-06 with a primary completion date of 2026-08-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Diffusion of local anesthetics after a lumbar ESPB within fascial planes towards nerve structures is a matter of debate. The main objective of the study is to compare the incidence of sensory block between two techniques of needle placement (superficial or translaminar) during lumbar ESPB block. Patients are treated with lumbar ESPB (randomized to superficial or translaminar), spinal anesthesia and multimodal analgesia. The primary endpoint will be the incidence of numbness/reduced skin sensitivity to cold (ice test) in the area innervated by the lumbar plexus. Secondary outcomes are pain and analgesic's consumption, motor block, quality of recovery and discharge ability.

Eligibility Criteria

Inclusion Criteria: * primary total hip replacement * informed consent Exclusion Criteria: * allergies to study drugs * spinal anesthesia contraindicated * kidney failure (GFR\<30) * epilepsy, psychiatric disease, neurologic deficits * revision surgery * neuropathies in the lumbar area (tingling, hypoestesia, numbness, motor deficit) * no informed consent * pregnancy * alcohol/opioid abuse * emergency surgery/intensive care

Contact & Investigator

Central Contact

Dario Bugada

✉ dariobugada@gmail.com

📞 +393405230454

Frequently Asked Questions

Who can join the NCT07104097 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hip Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07104097 currently recruiting?

Yes, NCT07104097 is actively recruiting participants. Contact the research team at dariobugada@gmail.com for enrollment information.

Where is the NCT07104097 trial being conducted?

This trial is being conducted at Bergamo, Italy.

Who is sponsoring the NCT07104097 clinical trial?

NCT07104097 is sponsored by Papa Giovanni XXIII Hospital. The trial plans to enroll 44 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology